Eli Lilly is spending billions on a new facility to make its popular weight loss drug ZepboundByBruce GilUpdatedMay 24, 2024
Ozempic knockoffs, Pfizer's cost-cutting, and AstraZeneca’s future: Pharma news roundupByBruce GilPublishedMay 24, 2024
Now playing More people are using marijuana daily than drinking for the first time in the U.S., study saysByBruce GilPublishedMay 23, 2024
Guardant Health's blood test to detect deadly colon cancer is under review by the FDAByBruce GilPublishedMay 23, 2024
Pfizer plans to cut costs by $1.5 billion as demand for COVID vaccine dwindlesByBruce GilPublishedMay 22, 2024
BuzzFeed stock surges after former presidential candidate Vivek Ramaswamy buys activist stakeByBruce GilPublishedMay 22, 2024
Novo Nordisk's experimental weekly insulin comes with a higher risk of low blood sugar, warns FDAByBruce GilPublishedMay 22, 2024
GSK says its experimental drug reduced asthma attacks with only two doses a yearByBruce GilPublishedMay 21, 2024
Hims & Hers is selling an Ozempic knockoff without FDA approval. Here's howByBruce GilPublishedMay 21, 2024
AstraZeneca aims increase its annual revenue by 75% in its post-COVID eraByBruce GilPublishedMay 21, 2024
Elon Musk's Neuralink got FDA approval to implant a brain chip in a second patientByBruce GilUpdatedMay 20, 2024
The rise of Ozempic: How a diabetes medication sparked the weight loss drug revolutionByBruce GilPublishedMay 20, 2024
Weight loss pills, Ozempic's big fan, and Merck's skin cancer drug: Pharma news roundupByBruce GilPublishedMay 17, 2024
Eli Lilly says its experimental weekly insulin works just as well as daily dosesByBruce GilUpdatedMay 16, 2024
An experimental weight loss drug helped users lose 18% of their weight in an early trialByBruce GilUpdatedMay 16, 2024
A Chinese biotech company poised for the U.S. blacklist has registered to lobby CongressByBruce GilPublishedMay 16, 2024
